Addition of oblimersen sodium to standard chemotherapy fails to improve outcomes in older AML patientsAugust 29, 2021AML
AML: Increased donor inhibitory KIR provides protection from relapse following HLA-matched unrelated donor HCTJuly 29, 2021AML
TP53-mutated AML: No survival benefit with addition of venetoclax to standard therapiesJuly 29, 2021AML
GM-EIA and BDG assays ineffective for IFD diagnosis in AML patients receiving antifungal prophylaxisJuly 29, 2021AML
AML with CBFB-MYH11: D816V KIT mutation and peri-transplant CBFB-MYH11 MRD positivity predict post-HSCT outcomesJuly 29, 2021AML
Conditioning regimen with Flu/Bu4/Mel vs conventional myeloablative conditioning improves survival in R/R AML patients in non-remissionJuly 29, 2021AML
Improved infection control with romyelocel-L in AML patients receiving induction chemotherapyJuly 29, 2021AML
CPX-351 vs standard chemotherapy continues to show improved OS in high-risk or secondary AML July 29, 2021AML
NPM1-mutated AML: CD33 SNP rs12459419 predicts relapse in gemtuzumab ozogamicin-treated patientsJune 24, 2021AML
